nodes	percent_of_prediction	percent_of_DWPC	metapath
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—PIM2—hematologic cancer	0.0151	0.12	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—LYL1—hematologic cancer	0.0114	0.0906	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—NSD1—hematologic cancer	0.00736	0.0584	CbGpPWpGaD
Valganciclovir—SLC6A14—Na+/Cl- dependent neurotransmitter transporters—SLC22A1—hematologic cancer	0.00702	0.0557	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—BCR—hematologic cancer	0.006	0.0476	CbGpPWpGaD
Valganciclovir—SLC6A14—Amine compound SLC transporters—SLC22A1—hematologic cancer	0.00487	0.0386	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—CSF1R—hematologic cancer	0.00423	0.0335	CbGpPWpGaD
Valganciclovir—Ganciclovir—SLC22A1—hematologic cancer	0.00415	0.562	CrCbGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—CCND3—hematologic cancer	0.00326	0.0259	CbGpPWpGaD
Valganciclovir—Aciclovir—SLC22A1—hematologic cancer	0.00323	0.437	CrCbGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—ABCG2—hematologic cancer	0.00293	0.0233	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A4—hematologic cancer	0.00293	0.0232	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—EPO—hematologic cancer	0.00252	0.02	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—CDK6—hematologic cancer	0.00243	0.0193	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A1—hematologic cancer	0.0019	0.0151	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—ABL1—hematologic cancer	0.00189	0.015	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—ABCB1—hematologic cancer	0.00183	0.0145	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—hematologic cancer	0.00173	0.0137	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—hematologic cancer	0.0017	0.0135	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—TXN—hematologic cancer	0.0015	0.0119	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—ABCC3—hematologic cancer	0.0015	0.0119	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC35B2—hematologic cancer	0.00147	0.0116	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—UGT1A1—hematologic cancer	0.00141	0.0112	CbGpPWpGaD
Valganciclovir—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A4—hematologic cancer	0.00139	0.011	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—hematologic cancer	0.00132	0.0105	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC26A4—hematologic cancer	0.00131	0.0104	CbGpPWpGaD
Valganciclovir—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A4—hematologic cancer	0.00129	0.0102	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—AQP9—hematologic cancer	0.00106	0.0084	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—FXYD6—hematologic cancer	0.000985	0.00781	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—NQO1—hematologic cancer	0.000968	0.00767	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—hematologic cancer	0.000948	0.00752	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—HSP90AA1—hematologic cancer	0.00091	0.00722	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC22A1—hematologic cancer	0.000866	0.00687	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—NUP98—hematologic cancer	0.000817	0.00648	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—GSTP1—hematologic cancer	0.000807	0.0064	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—S100A10—hematologic cancer	0.000803	0.00637	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—NUP214—hematologic cancer	0.000787	0.00625	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC35B2—hematologic cancer	0.000746	0.00592	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—HGF—hematologic cancer	0.000742	0.00588	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—GSTM1—hematologic cancer	0.000742	0.00588	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—hematologic cancer	0.000726	0.00576	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—ATP1B1—hematologic cancer	0.000702	0.00557	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC35B2—hematologic cancer	0.000695	0.00551	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC26A4—hematologic cancer	0.000665	0.00528	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC35B2—hematologic cancer	0.000645	0.00511	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—PDGFB—hematologic cancer	0.000638	0.00506	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC26A4—hematologic cancer	0.000619	0.00491	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—ANXA2—hematologic cancer	0.000608	0.00483	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SGK1—hematologic cancer	0.000608	0.00483	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—ATP4A—hematologic cancer	0.000608	0.00483	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC26A4—hematologic cancer	0.000575	0.00456	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	0.000548	0.00434	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—AQP9—hematologic cancer	0.000501	0.00397	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—ABCC3—hematologic cancer	0.000481	0.00381	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—FXYD6—hematologic cancer	0.000466	0.00369	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—AQP9—hematologic cancer	0.000465	0.00369	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	0.00044	0.00349	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—FXYD6—hematologic cancer	0.000432	0.00343	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—NUP98—hematologic cancer	0.000415	0.00329	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC22A1—hematologic cancer	0.000409	0.00325	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—ADCY7—hematologic cancer	0.000403	0.0032	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—NUP214—hematologic cancer	0.0004	0.00317	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—ABCG2—hematologic cancer	0.000392	0.00311	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—NUP98—hematologic cancer	0.000386	0.00306	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC22A1—hematologic cancer	0.00038	0.00301	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—S100A10—hematologic cancer	0.00038	0.00301	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—NUP214—hematologic cancer	0.000372	0.00295	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—NUP98—hematologic cancer	0.000359	0.00284	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC35B2—hematologic cancer	0.000353	0.0028	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—S100A10—hematologic cancer	0.000352	0.00279	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—TFRC—hematologic cancer	0.000349	0.00277	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—NUP214—hematologic cancer	0.000346	0.00274	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—ATP1B1—hematologic cancer	0.000332	0.00263	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC35B2—hematologic cancer	0.000328	0.0026	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC26A4—hematologic cancer	0.000315	0.0025	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—ATP1B1—hematologic cancer	0.000308	0.00244	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—TGFB1—hematologic cancer	0.000302	0.0024	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—ALB—hematologic cancer	0.000301	0.00239	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—CYCS—hematologic cancer	0.000293	0.00233	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC26A4—hematologic cancer	0.000292	0.00232	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—ATP4A—hematologic cancer	0.000288	0.00228	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SGK1—hematologic cancer	0.000288	0.00228	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—ANXA2—hematologic cancer	0.000288	0.00228	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—ANXA2—hematologic cancer	0.000267	0.00212	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SGK1—hematologic cancer	0.000267	0.00212	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—ATP4A—hematologic cancer	0.000267	0.00212	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	0.000259	0.00205	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—ABCB1—hematologic cancer	0.000245	0.00194	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	0.00024	0.00191	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—ABCC3—hematologic cancer	0.000227	0.0018	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—ABCC3—hematologic cancer	0.000211	0.00167	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	0.000208	0.00165	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—NUP98—hematologic cancer	0.000196	0.00156	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	0.000193	0.00153	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—ADCY7—hematologic cancer	0.000191	0.00151	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—NUP214—hematologic cancer	0.000189	0.0015	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—ABCG2—hematologic cancer	0.000185	0.00147	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—NUP98—hematologic cancer	0.000182	0.00145	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—ADCY7—hematologic cancer	0.000177	0.0014	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—NUP214—hematologic cancer	0.000176	0.00139	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—ABCG2—hematologic cancer	0.000172	0.00136	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—TFRC—hematologic cancer	0.000165	0.00131	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—CREBBP—hematologic cancer	0.000164	0.0013	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—TFRC—hematologic cancer	0.000153	0.00122	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—ALB—hematologic cancer	0.000153	0.00121	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—ALB—hematologic cancer	0.000142	0.00113	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—CYCS—hematologic cancer	0.000139	0.0011	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—ALB—hematologic cancer	0.000132	0.00105	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—CYCS—hematologic cancer	0.000129	0.00102	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—ABCB1—hematologic cancer	0.000116	0.000918	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—ABCB1—hematologic cancer	0.000107	0.000852	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—CREBBP—hematologic cancer	7.73e-05	0.000613	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—ALB—hematologic cancer	7.24e-05	0.000574	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	7.18e-05	0.000569	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—ALB—hematologic cancer	6.72e-05	0.000533	CbGpPWpGaD
Valganciclovir—Arrhythmia—Epirubicin—hematologic cancer	6.39e-05	7.37e-05	CcSEcCtD
Valganciclovir—Pain—Dexamethasone—hematologic cancer	6.38e-05	7.36e-05	CcSEcCtD
Valganciclovir—Pain—Betamethasone—hematologic cancer	6.38e-05	7.36e-05	CcSEcCtD
Valganciclovir—Visual impairment—Doxorubicin—hematologic cancer	6.38e-05	7.36e-05	CcSEcCtD
Valganciclovir—Nervous system disorder—Prednisone—hematologic cancer	6.37e-05	7.35e-05	CcSEcCtD
Valganciclovir—Tachycardia—Prednisone—hematologic cancer	6.34e-05	7.32e-05	CcSEcCtD
Valganciclovir—Alopecia—Epirubicin—hematologic cancer	6.32e-05	7.29e-05	CcSEcCtD
Valganciclovir—Skin disorder—Prednisone—hematologic cancer	6.31e-05	7.28e-05	CcSEcCtD
Valganciclovir—Nausea—Gemcitabine—hematologic cancer	6.3e-05	7.28e-05	CcSEcCtD
Valganciclovir—Vomiting—Cisplatin—hematologic cancer	6.29e-05	7.26e-05	CcSEcCtD
Valganciclovir—Hyperhidrosis—Prednisone—hematologic cancer	6.28e-05	7.25e-05	CcSEcCtD
Valganciclovir—Vision blurred—Methotrexate—hematologic cancer	6.27e-05	7.23e-05	CcSEcCtD
Valganciclovir—Mental disorder—Epirubicin—hematologic cancer	6.26e-05	7.23e-05	CcSEcCtD
Valganciclovir—Dermatitis—Cisplatin—hematologic cancer	6.23e-05	7.19e-05	CcSEcCtD
Valganciclovir—Malnutrition—Epirubicin—hematologic cancer	6.22e-05	7.18e-05	CcSEcCtD
Valganciclovir—Diarrhoea—Etoposide—hematologic cancer	6.2e-05	7.16e-05	CcSEcCtD
Valganciclovir—Anorexia—Prednisone—hematologic cancer	6.19e-05	7.15e-05	CcSEcCtD
Valganciclovir—Eye disorder—Doxorubicin—hematologic cancer	6.18e-05	7.14e-05	CcSEcCtD
Valganciclovir—Ill-defined disorder—Methotrexate—hematologic cancer	6.17e-05	7.12e-05	CcSEcCtD
Valganciclovir—Tinnitus—Doxorubicin—hematologic cancer	6.17e-05	7.12e-05	CcSEcCtD
Valganciclovir—Anaemia—Methotrexate—hematologic cancer	6.15e-05	7.09e-05	CcSEcCtD
Valganciclovir—Feeling abnormal—Dexamethasone—hematologic cancer	6.15e-05	7.09e-05	CcSEcCtD
Valganciclovir—Feeling abnormal—Betamethasone—hematologic cancer	6.15e-05	7.09e-05	CcSEcCtD
Valganciclovir—Cardiac disorder—Doxorubicin—hematologic cancer	6.14e-05	7.09e-05	CcSEcCtD
Valganciclovir—Flatulence—Epirubicin—hematologic cancer	6.13e-05	7.08e-05	CcSEcCtD
Valganciclovir—Tension—Epirubicin—hematologic cancer	6.11e-05	7.05e-05	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Dexamethasone—hematologic cancer	6.1e-05	7.04e-05	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Betamethasone—hematologic cancer	6.1e-05	7.04e-05	CcSEcCtD
Valganciclovir—Dysgeusia—Epirubicin—hematologic cancer	6.1e-05	7.03e-05	CcSEcCtD
Valganciclovir—Hypersensitivity—Triamcinolone—hematologic cancer	6.06e-05	6.99e-05	CcSEcCtD
Valganciclovir—Nervousness—Epirubicin—hematologic cancer	6.05e-05	6.98e-05	CcSEcCtD
Valganciclovir—Back pain—Epirubicin—hematologic cancer	6.02e-05	6.95e-05	CcSEcCtD
Valganciclovir—Angiopathy—Doxorubicin—hematologic cancer	6e-05	6.93e-05	CcSEcCtD
Valganciclovir—Malaise—Methotrexate—hematologic cancer	6e-05	6.92e-05	CcSEcCtD
Valganciclovir—Dizziness—Etoposide—hematologic cancer	5.99e-05	6.92e-05	CcSEcCtD
Valganciclovir—Muscle spasms—Epirubicin—hematologic cancer	5.98e-05	6.91e-05	CcSEcCtD
Valganciclovir—Immune system disorder—Doxorubicin—hematologic cancer	5.98e-05	6.9e-05	CcSEcCtD
Valganciclovir—Vertigo—Methotrexate—hematologic cancer	5.98e-05	6.9e-05	CcSEcCtD
Valganciclovir—Mediastinal disorder—Doxorubicin—hematologic cancer	5.96e-05	6.88e-05	CcSEcCtD
Valganciclovir—Leukopenia—Methotrexate—hematologic cancer	5.95e-05	6.87e-05	CcSEcCtD
Valganciclovir—Chills—Doxorubicin—hematologic cancer	5.94e-05	6.85e-05	CcSEcCtD
Valganciclovir—Urticaria—Betamethasone—hematologic cancer	5.93e-05	6.84e-05	CcSEcCtD
Valganciclovir—Urticaria—Dexamethasone—hematologic cancer	5.93e-05	6.84e-05	CcSEcCtD
Valganciclovir—Musculoskeletal discomfort—Prednisone—hematologic cancer	5.92e-05	6.83e-05	CcSEcCtD
Valganciclovir—Dizziness—Prednisolone—hematologic cancer	5.91e-05	6.82e-05	CcSEcCtD
Valganciclovir—Arrhythmia—Doxorubicin—hematologic cancer	5.91e-05	6.82e-05	CcSEcCtD
Valganciclovir—Asthenia—Triamcinolone—hematologic cancer	5.9e-05	6.81e-05	CcSEcCtD
Valganciclovir—Body temperature increased—Betamethasone—hematologic cancer	5.9e-05	6.8e-05	CcSEcCtD
Valganciclovir—Abdominal pain—Dexamethasone—hematologic cancer	5.9e-05	6.8e-05	CcSEcCtD
Valganciclovir—Abdominal pain—Betamethasone—hematologic cancer	5.9e-05	6.8e-05	CcSEcCtD
Valganciclovir—Body temperature increased—Dexamethasone—hematologic cancer	5.9e-05	6.8e-05	CcSEcCtD
Valganciclovir—Nausea—Cisplatin—hematologic cancer	5.88e-05	6.78e-05	CcSEcCtD
Valganciclovir—Insomnia—Prednisone—hematologic cancer	5.88e-05	6.78e-05	CcSEcCtD
Valganciclovir—Vision blurred—Epirubicin—hematologic cancer	5.87e-05	6.77e-05	CcSEcCtD
Valganciclovir—Alopecia—Doxorubicin—hematologic cancer	5.85e-05	6.75e-05	CcSEcCtD
Valganciclovir—Paraesthesia—Prednisone—hematologic cancer	5.83e-05	6.73e-05	CcSEcCtD
Valganciclovir—Pruritus—Triamcinolone—hematologic cancer	5.82e-05	6.71e-05	CcSEcCtD
Valganciclovir—Cough—Methotrexate—hematologic cancer	5.8e-05	6.7e-05	CcSEcCtD
Valganciclovir—Mental disorder—Doxorubicin—hematologic cancer	5.8e-05	6.69e-05	CcSEcCtD
Valganciclovir—Ill-defined disorder—Epirubicin—hematologic cancer	5.78e-05	6.67e-05	CcSEcCtD
Valganciclovir—Convulsion—Methotrexate—hematologic cancer	5.76e-05	6.65e-05	CcSEcCtD
Valganciclovir—Vomiting—Etoposide—hematologic cancer	5.76e-05	6.65e-05	CcSEcCtD
Valganciclovir—Malnutrition—Doxorubicin—hematologic cancer	5.76e-05	6.65e-05	CcSEcCtD
Valganciclovir—Anaemia—Epirubicin—hematologic cancer	5.75e-05	6.64e-05	CcSEcCtD
Valganciclovir—Agitation—Epirubicin—hematologic cancer	5.72e-05	6.6e-05	CcSEcCtD
Valganciclovir—Dyspepsia—Prednisone—hematologic cancer	5.72e-05	6.6e-05	CcSEcCtD
Valganciclovir—Dermatitis—Etoposide—hematologic cancer	5.71e-05	6.59e-05	CcSEcCtD
Valganciclovir—Headache—Etoposide—hematologic cancer	5.68e-05	6.55e-05	CcSEcCtD
Valganciclovir—Flatulence—Doxorubicin—hematologic cancer	5.68e-05	6.55e-05	CcSEcCtD
Valganciclovir—Arthralgia—Methotrexate—hematologic cancer	5.66e-05	6.54e-05	CcSEcCtD
Valganciclovir—Tension—Doxorubicin—hematologic cancer	5.65e-05	6.52e-05	CcSEcCtD
Valganciclovir—Decreased appetite—Prednisone—hematologic cancer	5.65e-05	6.52e-05	CcSEcCtD
Valganciclovir—Dysgeusia—Doxorubicin—hematologic cancer	5.64e-05	6.51e-05	CcSEcCtD
Valganciclovir—Dermatitis—Prednisolone—hematologic cancer	5.63e-05	6.5e-05	CcSEcCtD
Valganciclovir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	5.62e-05	6.49e-05	CcSEcCtD
Valganciclovir—Malaise—Epirubicin—hematologic cancer	5.61e-05	6.48e-05	CcSEcCtD
Valganciclovir—Fatigue—Prednisone—hematologic cancer	5.6e-05	6.46e-05	CcSEcCtD
Valganciclovir—Headache—Prednisolone—hematologic cancer	5.6e-05	6.46e-05	CcSEcCtD
Valganciclovir—Discomfort—Methotrexate—hematologic cancer	5.6e-05	6.46e-05	CcSEcCtD
Valganciclovir—Nervousness—Doxorubicin—hematologic cancer	5.59e-05	6.46e-05	CcSEcCtD
Valganciclovir—Vertigo—Epirubicin—hematologic cancer	5.59e-05	6.45e-05	CcSEcCtD
Valganciclovir—Leukopenia—Epirubicin—hematologic cancer	5.57e-05	6.43e-05	CcSEcCtD
Valganciclovir—Back pain—Doxorubicin—hematologic cancer	5.57e-05	6.43e-05	CcSEcCtD
Valganciclovir—Constipation—Prednisone—hematologic cancer	5.55e-05	6.41e-05	CcSEcCtD
Valganciclovir—Muscle spasms—Doxorubicin—hematologic cancer	5.54e-05	6.39e-05	CcSEcCtD
Valganciclovir—Confusional state—Methotrexate—hematologic cancer	5.47e-05	6.32e-05	CcSEcCtD
Valganciclovir—Dizziness—Triamcinolone—hematologic cancer	5.44e-05	6.27e-05	CcSEcCtD
Valganciclovir—Cough—Epirubicin—hematologic cancer	5.43e-05	6.27e-05	CcSEcCtD
Valganciclovir—Anaphylactic shock—Methotrexate—hematologic cancer	5.43e-05	6.26e-05	CcSEcCtD
Valganciclovir—Vision blurred—Doxorubicin—hematologic cancer	5.43e-05	6.26e-05	CcSEcCtD
Valganciclovir—Convulsion—Epirubicin—hematologic cancer	5.39e-05	6.22e-05	CcSEcCtD
Valganciclovir—Infection—Methotrexate—hematologic cancer	5.39e-05	6.22e-05	CcSEcCtD
Valganciclovir—Nausea—Etoposide—hematologic cancer	5.38e-05	6.21e-05	CcSEcCtD
Valganciclovir—Hypertension—Epirubicin—hematologic cancer	5.37e-05	6.2e-05	CcSEcCtD
Valganciclovir—Feeling abnormal—Prednisone—hematologic cancer	5.35e-05	6.18e-05	CcSEcCtD
Valganciclovir—Asthenia—Dexamethasone—hematologic cancer	5.35e-05	6.18e-05	CcSEcCtD
Valganciclovir—Asthenia—Betamethasone—hematologic cancer	5.35e-05	6.18e-05	CcSEcCtD
Valganciclovir—Ill-defined disorder—Doxorubicin—hematologic cancer	5.34e-05	6.17e-05	CcSEcCtD
Valganciclovir—Nervous system disorder—Methotrexate—hematologic cancer	5.32e-05	6.14e-05	CcSEcCtD
Valganciclovir—Anaemia—Doxorubicin—hematologic cancer	5.32e-05	6.14e-05	CcSEcCtD
Valganciclovir—Thrombocytopenia—Methotrexate—hematologic cancer	5.32e-05	6.13e-05	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Prednisone—hematologic cancer	5.31e-05	6.13e-05	CcSEcCtD
Valganciclovir—Nausea—Prednisolone—hematologic cancer	5.31e-05	6.13e-05	CcSEcCtD
Valganciclovir—Arthralgia—Epirubicin—hematologic cancer	5.3e-05	6.12e-05	CcSEcCtD
Valganciclovir—Agitation—Doxorubicin—hematologic cancer	5.29e-05	6.11e-05	CcSEcCtD
Valganciclovir—Anxiety—Epirubicin—hematologic cancer	5.28e-05	6.09e-05	CcSEcCtD
Valganciclovir—Pruritus—Dexamethasone—hematologic cancer	5.28e-05	6.09e-05	CcSEcCtD
Valganciclovir—Pruritus—Betamethasone—hematologic cancer	5.28e-05	6.09e-05	CcSEcCtD
Valganciclovir—Skin disorder—Methotrexate—hematologic cancer	5.27e-05	6.09e-05	CcSEcCtD
Valganciclovir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	5.26e-05	6.07e-05	CcSEcCtD
Valganciclovir—Hyperhidrosis—Methotrexate—hematologic cancer	5.25e-05	6.06e-05	CcSEcCtD
Valganciclovir—Discomfort—Epirubicin—hematologic cancer	5.24e-05	6.04e-05	CcSEcCtD
Valganciclovir—Vomiting—Triamcinolone—hematologic cancer	5.23e-05	6.03e-05	CcSEcCtD
Valganciclovir—Malaise—Doxorubicin—hematologic cancer	5.19e-05	5.99e-05	CcSEcCtD
Valganciclovir—Dry mouth—Epirubicin—hematologic cancer	5.18e-05	5.98e-05	CcSEcCtD
Valganciclovir—Dermatitis—Triamcinolone—hematologic cancer	5.18e-05	5.98e-05	CcSEcCtD
Valganciclovir—Vertigo—Doxorubicin—hematologic cancer	5.17e-05	5.97e-05	CcSEcCtD
Valganciclovir—Anorexia—Methotrexate—hematologic cancer	5.17e-05	5.97e-05	CcSEcCtD
Valganciclovir—Urticaria—Prednisone—hematologic cancer	5.16e-05	5.96e-05	CcSEcCtD
Valganciclovir—Leukopenia—Doxorubicin—hematologic cancer	5.16e-05	5.95e-05	CcSEcCtD
Valganciclovir—Headache—Triamcinolone—hematologic cancer	5.15e-05	5.94e-05	CcSEcCtD
Valganciclovir—Body temperature increased—Prednisone—hematologic cancer	5.13e-05	5.93e-05	CcSEcCtD
Valganciclovir—Abdominal pain—Prednisone—hematologic cancer	5.13e-05	5.93e-05	CcSEcCtD
Valganciclovir—Confusional state—Epirubicin—hematologic cancer	5.12e-05	5.91e-05	CcSEcCtD
Valganciclovir—Diarrhoea—Dexamethasone—hematologic cancer	5.1e-05	5.89e-05	CcSEcCtD
Valganciclovir—Diarrhoea—Betamethasone—hematologic cancer	5.1e-05	5.89e-05	CcSEcCtD
Valganciclovir—Anaphylactic shock—Epirubicin—hematologic cancer	5.08e-05	5.86e-05	CcSEcCtD
Valganciclovir—Oedema—Epirubicin—hematologic cancer	5.08e-05	5.86e-05	CcSEcCtD
Valganciclovir—Hypotension—Methotrexate—hematologic cancer	5.07e-05	5.85e-05	CcSEcCtD
Valganciclovir—Infection—Epirubicin—hematologic cancer	5.05e-05	5.82e-05	CcSEcCtD
Valganciclovir—Cough—Doxorubicin—hematologic cancer	5.03e-05	5.8e-05	CcSEcCtD
Valganciclovir—Convulsion—Doxorubicin—hematologic cancer	4.99e-05	5.76e-05	CcSEcCtD
Valganciclovir—Nervous system disorder—Epirubicin—hematologic cancer	4.98e-05	5.75e-05	CcSEcCtD
Valganciclovir—Thrombocytopenia—Epirubicin—hematologic cancer	4.97e-05	5.74e-05	CcSEcCtD
Valganciclovir—Hypertension—Doxorubicin—hematologic cancer	4.97e-05	5.74e-05	CcSEcCtD
Valganciclovir—Tachycardia—Epirubicin—hematologic cancer	4.96e-05	5.72e-05	CcSEcCtD
Valganciclovir—Musculoskeletal discomfort—Methotrexate—hematologic cancer	4.95e-05	5.71e-05	CcSEcCtD
Valganciclovir—Skin disorder—Epirubicin—hematologic cancer	4.93e-05	5.69e-05	CcSEcCtD
Valganciclovir—Dizziness—Dexamethasone—hematologic cancer	4.93e-05	5.69e-05	CcSEcCtD
Valganciclovir—Dizziness—Betamethasone—hematologic cancer	4.93e-05	5.69e-05	CcSEcCtD
Valganciclovir—Hyperhidrosis—Epirubicin—hematologic cancer	4.91e-05	5.67e-05	CcSEcCtD
Valganciclovir—Insomnia—Methotrexate—hematologic cancer	4.91e-05	5.67e-05	CcSEcCtD
Valganciclovir—Arthralgia—Doxorubicin—hematologic cancer	4.9e-05	5.66e-05	CcSEcCtD
Valganciclovir—Anxiety—Doxorubicin—hematologic cancer	4.89e-05	5.64e-05	CcSEcCtD
Valganciclovir—Nausea—Triamcinolone—hematologic cancer	4.88e-05	5.63e-05	CcSEcCtD
Valganciclovir—Paraesthesia—Methotrexate—hematologic cancer	4.87e-05	5.63e-05	CcSEcCtD
Valganciclovir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	4.87e-05	5.62e-05	CcSEcCtD
Valganciclovir—Discomfort—Doxorubicin—hematologic cancer	4.84e-05	5.59e-05	CcSEcCtD
Valganciclovir—Anorexia—Epirubicin—hematologic cancer	4.84e-05	5.59e-05	CcSEcCtD
Valganciclovir—Dyspnoea—Methotrexate—hematologic cancer	4.84e-05	5.59e-05	CcSEcCtD
Valganciclovir—Somnolence—Methotrexate—hematologic cancer	4.83e-05	5.57e-05	CcSEcCtD
Valganciclovir—Dry mouth—Doxorubicin—hematologic cancer	4.8e-05	5.53e-05	CcSEcCtD
Valganciclovir—Hypersensitivity—Prednisone—hematologic cancer	4.79e-05	5.52e-05	CcSEcCtD
Valganciclovir—Dyspepsia—Methotrexate—hematologic cancer	4.78e-05	5.51e-05	CcSEcCtD
Valganciclovir—Hypotension—Epirubicin—hematologic cancer	4.75e-05	5.48e-05	CcSEcCtD
Valganciclovir—Vomiting—Betamethasone—hematologic cancer	4.74e-05	5.47e-05	CcSEcCtD
Valganciclovir—Vomiting—Dexamethasone—hematologic cancer	4.74e-05	5.47e-05	CcSEcCtD
Valganciclovir—Confusional state—Doxorubicin—hematologic cancer	4.74e-05	5.47e-05	CcSEcCtD
Valganciclovir—Decreased appetite—Methotrexate—hematologic cancer	4.72e-05	5.45e-05	CcSEcCtD
Valganciclovir—Oedema—Doxorubicin—hematologic cancer	4.7e-05	5.42e-05	CcSEcCtD
Valganciclovir—Anaphylactic shock—Doxorubicin—hematologic cancer	4.7e-05	5.42e-05	CcSEcCtD
Valganciclovir—Dermatitis—Dexamethasone—hematologic cancer	4.7e-05	5.42e-05	CcSEcCtD
Valganciclovir—Dermatitis—Betamethasone—hematologic cancer	4.7e-05	5.42e-05	CcSEcCtD
Valganciclovir—Gastrointestinal disorder—Methotrexate—hematologic cancer	4.69e-05	5.41e-05	CcSEcCtD
Valganciclovir—Fatigue—Methotrexate—hematologic cancer	4.68e-05	5.4e-05	CcSEcCtD
Valganciclovir—Headache—Dexamethasone—hematologic cancer	4.67e-05	5.39e-05	CcSEcCtD
Valganciclovir—Headache—Betamethasone—hematologic cancer	4.67e-05	5.39e-05	CcSEcCtD
Valganciclovir—Infection—Doxorubicin—hematologic cancer	4.67e-05	5.39e-05	CcSEcCtD
Valganciclovir—Asthenia—Prednisone—hematologic cancer	4.66e-05	5.38e-05	CcSEcCtD
Valganciclovir—Pain—Methotrexate—hematologic cancer	4.64e-05	5.36e-05	CcSEcCtD
Valganciclovir—Musculoskeletal discomfort—Epirubicin—hematologic cancer	4.63e-05	5.34e-05	CcSEcCtD
Valganciclovir—Nervous system disorder—Doxorubicin—hematologic cancer	4.61e-05	5.32e-05	CcSEcCtD
Valganciclovir—Thrombocytopenia—Doxorubicin—hematologic cancer	4.6e-05	5.31e-05	CcSEcCtD
Valganciclovir—Pruritus—Prednisone—hematologic cancer	4.6e-05	5.3e-05	CcSEcCtD
Valganciclovir—Insomnia—Epirubicin—hematologic cancer	4.59e-05	5.3e-05	CcSEcCtD
Valganciclovir—Tachycardia—Doxorubicin—hematologic cancer	4.59e-05	5.29e-05	CcSEcCtD
Valganciclovir—Skin disorder—Doxorubicin—hematologic cancer	4.57e-05	5.27e-05	CcSEcCtD
Valganciclovir—Paraesthesia—Epirubicin—hematologic cancer	4.56e-05	5.26e-05	CcSEcCtD
Valganciclovir—Hyperhidrosis—Doxorubicin—hematologic cancer	4.54e-05	5.24e-05	CcSEcCtD
Valganciclovir—Dyspnoea—Epirubicin—hematologic cancer	4.53e-05	5.23e-05	CcSEcCtD
Valganciclovir—Somnolence—Epirubicin—hematologic cancer	4.52e-05	5.21e-05	CcSEcCtD
Valganciclovir—Anorexia—Doxorubicin—hematologic cancer	4.48e-05	5.17e-05	CcSEcCtD
Valganciclovir—Feeling abnormal—Methotrexate—hematologic cancer	4.47e-05	5.16e-05	CcSEcCtD
Valganciclovir—Dyspepsia—Epirubicin—hematologic cancer	4.47e-05	5.16e-05	CcSEcCtD
Valganciclovir—Diarrhoea—Prednisone—hematologic cancer	4.44e-05	5.13e-05	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Methotrexate—hematologic cancer	4.44e-05	5.12e-05	CcSEcCtD
Valganciclovir—Nausea—Betamethasone—hematologic cancer	4.43e-05	5.11e-05	CcSEcCtD
Valganciclovir—Nausea—Dexamethasone—hematologic cancer	4.43e-05	5.11e-05	CcSEcCtD
Valganciclovir—Decreased appetite—Epirubicin—hematologic cancer	4.42e-05	5.1e-05	CcSEcCtD
Valganciclovir—Hypotension—Doxorubicin—hematologic cancer	4.39e-05	5.07e-05	CcSEcCtD
Valganciclovir—Gastrointestinal disorder—Epirubicin—hematologic cancer	4.39e-05	5.06e-05	CcSEcCtD
Valganciclovir—Fatigue—Epirubicin—hematologic cancer	4.38e-05	5.05e-05	CcSEcCtD
Valganciclovir—Pain—Epirubicin—hematologic cancer	4.34e-05	5.01e-05	CcSEcCtD
Valganciclovir—Constipation—Epirubicin—hematologic cancer	4.34e-05	5.01e-05	CcSEcCtD
Valganciclovir—Urticaria—Methotrexate—hematologic cancer	4.31e-05	4.98e-05	CcSEcCtD
Valganciclovir—Dizziness—Prednisone—hematologic cancer	4.3e-05	4.96e-05	CcSEcCtD
Valganciclovir—Abdominal pain—Methotrexate—hematologic cancer	4.29e-05	4.95e-05	CcSEcCtD
Valganciclovir—Body temperature increased—Methotrexate—hematologic cancer	4.29e-05	4.95e-05	CcSEcCtD
Valganciclovir—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	4.28e-05	4.94e-05	CcSEcCtD
Valganciclovir—Insomnia—Doxorubicin—hematologic cancer	4.25e-05	4.91e-05	CcSEcCtD
Valganciclovir—Paraesthesia—Doxorubicin—hematologic cancer	4.22e-05	4.87e-05	CcSEcCtD
Valganciclovir—Dyspnoea—Doxorubicin—hematologic cancer	4.19e-05	4.84e-05	CcSEcCtD
Valganciclovir—Feeling abnormal—Epirubicin—hematologic cancer	4.19e-05	4.83e-05	CcSEcCtD
Valganciclovir—Somnolence—Doxorubicin—hematologic cancer	4.18e-05	4.82e-05	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Epirubicin—hematologic cancer	4.15e-05	4.79e-05	CcSEcCtD
Valganciclovir—Dyspepsia—Doxorubicin—hematologic cancer	4.14e-05	4.78e-05	CcSEcCtD
Valganciclovir—Vomiting—Prednisone—hematologic cancer	4.13e-05	4.77e-05	CcSEcCtD
Valganciclovir—Dermatitis—Prednisone—hematologic cancer	4.09e-05	4.72e-05	CcSEcCtD
Valganciclovir—Decreased appetite—Doxorubicin—hematologic cancer	4.09e-05	4.72e-05	CcSEcCtD
Valganciclovir—Headache—Prednisone—hematologic cancer	4.07e-05	4.7e-05	CcSEcCtD
Valganciclovir—Gastrointestinal disorder—Doxorubicin—hematologic cancer	4.06e-05	4.68e-05	CcSEcCtD
Valganciclovir—Fatigue—Doxorubicin—hematologic cancer	4.05e-05	4.68e-05	CcSEcCtD
Valganciclovir—Urticaria—Epirubicin—hematologic cancer	4.04e-05	4.66e-05	CcSEcCtD
Valganciclovir—Constipation—Doxorubicin—hematologic cancer	4.02e-05	4.64e-05	CcSEcCtD
Valganciclovir—Pain—Doxorubicin—hematologic cancer	4.02e-05	4.64e-05	CcSEcCtD
Valganciclovir—Abdominal pain—Epirubicin—hematologic cancer	4.02e-05	4.63e-05	CcSEcCtD
Valganciclovir—Body temperature increased—Epirubicin—hematologic cancer	4.02e-05	4.63e-05	CcSEcCtD
Valganciclovir—Hypersensitivity—Methotrexate—hematologic cancer	4e-05	4.62e-05	CcSEcCtD
Valganciclovir—Asthenia—Methotrexate—hematologic cancer	3.89e-05	4.49e-05	CcSEcCtD
Valganciclovir—Feeling abnormal—Doxorubicin—hematologic cancer	3.87e-05	4.47e-05	CcSEcCtD
Valganciclovir—Nausea—Prednisone—hematologic cancer	3.86e-05	4.45e-05	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Doxorubicin—hematologic cancer	3.84e-05	4.44e-05	CcSEcCtD
Valganciclovir—Pruritus—Methotrexate—hematologic cancer	3.84e-05	4.43e-05	CcSEcCtD
Valganciclovir—Hypersensitivity—Epirubicin—hematologic cancer	3.74e-05	4.32e-05	CcSEcCtD
Valganciclovir—Urticaria—Doxorubicin—hematologic cancer	3.73e-05	4.31e-05	CcSEcCtD
Valganciclovir—Abdominal pain—Doxorubicin—hematologic cancer	3.72e-05	4.29e-05	CcSEcCtD
Valganciclovir—Body temperature increased—Doxorubicin—hematologic cancer	3.72e-05	4.29e-05	CcSEcCtD
Valganciclovir—Diarrhoea—Methotrexate—hematologic cancer	3.71e-05	4.29e-05	CcSEcCtD
Valganciclovir—Asthenia—Epirubicin—hematologic cancer	3.65e-05	4.21e-05	CcSEcCtD
Valganciclovir—Pruritus—Epirubicin—hematologic cancer	3.59e-05	4.15e-05	CcSEcCtD
Valganciclovir—Dizziness—Methotrexate—hematologic cancer	3.59e-05	4.14e-05	CcSEcCtD
Valganciclovir—Diarrhoea—Epirubicin—hematologic cancer	3.48e-05	4.01e-05	CcSEcCtD
Valganciclovir—Hypersensitivity—Doxorubicin—hematologic cancer	3.46e-05	4e-05	CcSEcCtD
Valganciclovir—Vomiting—Methotrexate—hematologic cancer	3.45e-05	3.98e-05	CcSEcCtD
Valganciclovir—Dermatitis—Methotrexate—hematologic cancer	3.42e-05	3.95e-05	CcSEcCtD
Valganciclovir—Headache—Methotrexate—hematologic cancer	3.4e-05	3.92e-05	CcSEcCtD
Valganciclovir—Asthenia—Doxorubicin—hematologic cancer	3.37e-05	3.89e-05	CcSEcCtD
Valganciclovir—Dizziness—Epirubicin—hematologic cancer	3.36e-05	3.88e-05	CcSEcCtD
Valganciclovir—Pruritus—Doxorubicin—hematologic cancer	3.33e-05	3.84e-05	CcSEcCtD
Valganciclovir—Vomiting—Epirubicin—hematologic cancer	3.23e-05	3.73e-05	CcSEcCtD
Valganciclovir—Nausea—Methotrexate—hematologic cancer	3.22e-05	3.72e-05	CcSEcCtD
Valganciclovir—Diarrhoea—Doxorubicin—hematologic cancer	3.22e-05	3.71e-05	CcSEcCtD
Valganciclovir—Dermatitis—Epirubicin—hematologic cancer	3.2e-05	3.69e-05	CcSEcCtD
Valganciclovir—Headache—Epirubicin—hematologic cancer	3.18e-05	3.67e-05	CcSEcCtD
Valganciclovir—Dizziness—Doxorubicin—hematologic cancer	3.11e-05	3.59e-05	CcSEcCtD
Valganciclovir—Nausea—Epirubicin—hematologic cancer	3.02e-05	3.48e-05	CcSEcCtD
Valganciclovir—Vomiting—Doxorubicin—hematologic cancer	2.99e-05	3.45e-05	CcSEcCtD
Valganciclovir—Dermatitis—Doxorubicin—hematologic cancer	2.96e-05	3.42e-05	CcSEcCtD
Valganciclovir—Headache—Doxorubicin—hematologic cancer	2.94e-05	3.4e-05	CcSEcCtD
Valganciclovir—Nausea—Doxorubicin—hematologic cancer	2.79e-05	3.22e-05	CcSEcCtD
